Human interventions, namely, mistreatment of tuberculosis (TB) and poor patient compliance, selectively favor the multiplication of drug-resistant Mycobacterium tuberculosis mutants over drug-susceptible bacilli in tuberculous lesions. M. tuberculosis isolates are considered to be multidrug resistant (MDR) when showing resistance to isoniazid and rifampin (rifampicin), the most effective drugs for TB treatment; they become extensively drug resistant when showing additional resistance to key second-line drugs (32, 36) . MDR-TB and extensively drug-resistant TB are very difficult to treat, their prognosis is somber, and mortality is high (14, 27) .
In Argentina, a total of 11,464 new cases of TB were reported in 2006, with an incidence of 29.1 per 100,000 inhabitants. MDR-TB occurred in 4.5% of the cases. MDR-TB outbreaks emerged in Argentina among hospitalized patients with AIDS in the early 1990s (1, 45) and thereafter disseminated to immunocompetent individuals (37) (38) (39) . Epidemiological, bacteriological, and genotyping data allowed the identification of certain MDR M. tuberculosis outbreak strains, such as the so-called strain M of the Haarlem family and strain Ra of the Latin America and Mediterranean (LAM) family. Each of these two strains managed to perpetuate in its geographical niche, i.e., Buenos Aires and the Rosario City area, respectively. In particular, strain M appears to be highly prosperous in the country and is able to build up further drug resistance without impairing its ability to spread (29) .
TB development depends not only on the host immune response and on its natural resistance/susceptibility to M. tuberculosis infection but also on differences in transmissibility, virulence, and immunogenicity among M. tuberculosis strains, determined by the genetic background of the organisms. It is becoming evident that certain strains of M. tuberculosis with special transmission potential are able to manipulate host immunity by inducing Th1 or Th2 responses which could impact disease outcome and/or evolution (5, 28, 30, 31, (40) (41) (42) 51) . Protective immunity against TB is mediated by a Th1-type immune response characterized by high levels of interleukin-12 (IL-12) from infected macrophages and gamma interferon (IFN-␥) from antigen-specific T cells, which control and contain infection in the lungs (24) . Peripheral blood mononuclear cells (PBMC) from MDR-TB patients have been shown to poorly respond in vitro to H37Ra whole bacilli, purified protein derivative (PPD), and specific antigens, such as ESAT-6 and the 30-kDa protein (16, 25, 26, 33) . Furthermore, increased IL-4 secretion by CD4 ϩ T cells after H37Rv total lipid stimulation was observed in MDR-TB patients (50) .
Although a Th1 profile is necessary for a protective response, it may also cause immunopathologic damage; for this reason, either regulatory T cells (Treg cells) or a Th2 response might play important regulatory functions protecting the patient from collateral host tissue damage. Nevertheless, an excessive Th1 downregulation might favor disease progression. In this context, increased levels of CD4 ϩ CD25 high Foxp3 ϩ Treg cells have been detected in PBMC from drug-susceptible tuberculosis (S-TB) patients compared to those from PPDpositive (PPD ϩ ) healthy donors (18) (19) (20) 46) . In addition, the results of studies involving in vitro depletion of CD4 ϩ
CD25
high T lymphocytes suggest a role of Treg cells in TB pathogenesis (18) (19) (20) 43 ).
In the current study, we examined immune profiles induced by two MDR M. tuberculosis strains disseminated in Argentina, namely, strains M and Ra. Our results demonstrate that strain M is a weak inducer of IFN-␥ and elicits a remarkably low cytotoxic T-cell (CTL) activity. Also, in vitro expansion of Treg cells in PBMC from TB patients is not M. tuberculosis strain dependent and efficiently suppresses antigen-induced IFN-␥ and CTL responses.
MATERIALS AND METHODS
Patients and isolates. Blood samples were obtained from MDR-TB and S-TB patients hospitalized in the Phthisio-Pneumonology Institute University of Buenos Aires, placed in the F. J. Muñiz Hospital, Buenos Aires, Argentina. Informed consent was obtained from patients according to the guidelines of the ethics committee of the F. J. Muñiz Hospital. All patients were diagnosed by the presence of recent clinical respiratory symptoms, abnormal chest radiography, a positive sputum smear test for acid-fast bacilli, and the identification of M. tuberculosis in culture. Exclusion criteria included a positive test for human immunodeficiency virus (HIV) and the presence of concurrent infectious diseases or noninfectious conditions (cancer, diabetes, or steroid therapy).
Sputum smear examination, mycobacterial culture, species identification, and drug susceptibility testing were performed according to standard procedures. Susceptibility to isoniazid, rifampin, ethambutol, and streptomycin was determined according to World Health Organization standards. Susceptibility to kanamycin, p-aminosalicylic acid, and cycloserine was tested according to the Canetti, Rist, and Grosset method, whereas the pyrazinamidase test was used to infer pyrazinamide susceptibility (59) . Available MDR M. tuberculosis isolates were genotyped by IS6110 DNA fingerprinting and spoligotyping, using standardized protocols (23, 58 Thermo Scientific, UT) containing 100 U/ml penicillin, 100 g/ml streptomycin, and 10% heat-inactivated fetal calf serum (Invitrogen, Gibco) (complete medium).
CD25 cell depletion. PBMC (1 ϫ 10 7 ) were incubated with 1 g anti-CD25 monoclonal antibody (MAb; eBioscience, San Diego, CA) for 30 min at 4°C, washed with phosphate-buffered saline (PBS), and mixed with goat anti-mouse immunoglobulin G-coated magnetic beads (Invitrogen Dynal, Oslo, Norway) by gentle rolling at 4°C for 30 min. Nonrosetted cells (CD25-depleted PBMC) were enriched using a magnet. Generally, one cycle of treatment was sufficient for an effective depletion, as assessed by flow cytometry: approximately 80 to 98% of CD4 ϩ CD25 high T cells were eliminated after depletion, and a reduction of CD4 ϩ CD25 low T cells was observed (27 to 45%) in CD25-depleted PBMC. CD8 ϩ CD25 ϩ T cells were slightly reduced (5 to 28%) after depletion. CD25-depleted PBMC were suspended in complete medium, ensuring that the number of cells/ml of each subset was the same as in total cultured PBMC in order to compare their cytokine production and CD107 expression.
Antigens. MDR outbreak strains M (Haarlem family) and Ra (LAM family), as well as laboratory strain H37Rv (T family), were grown in Middlebrook 7H9 broth (Difco Laboratories, Detroit, MI) at 37°C in 5% CO 2 until log phase. Strain 410, an MDR strain of the Haarlem family that is highly related but not identical to strain M, was included in some experiments (Fig. 1 ). Mycobacteria were harvested, washed three times, and suspended in PBS that was free of pyrogens. Bacteria were killed by heating at 80°C for 1 h, suspended in PBS at an optical density at 600 nm of 1 (Ϸ10 8 bacteria/ml), and stored at Ϫ20°C until use. These mycobacterial suspensions contained soluble as well as particulate antigens.
PBMC cultures. Total or CD25-depleted PBMC (2 ϫ 10 6 cells/ml) were cultured in polystyrene tubes (BD Falcon, Franklin Lakes, NJ) at 37°C in a humidified 5% CO 2 atmosphere in complete medium in the presence of heatkilled bacilli (suspensions of M. tuberculosis strain M, Ra, 410, or H37Rv at a 2:1 ratio of M. tuberculosis to PBMC).
51
Cr release cytotoxic assay. The ability of PBMC stimulated by M, Ra, 410, or H37Rv killed bacilli (effector cells) to lyse autologous M. tuberculosis-pulsed macrophages was examined using a standard chromium release cytotoxicity assay as described previously (12) .
Immunofluorescence analysis. (i) Surface membrane expression. The following MAbs were used to evaluate surface marker expression in fresh and 5-daycultured PBMC: anti-CD4 (Cy5-phycoerythrin [Cy5-PE] or fluorescein isothiocyanate [FITC] conjugated), anti-CD8 (Cy5-PE or PE conjugated) (both from BD Bioscience, San Jose, CA), and PE-conjugated anti-CD25 (eBioscience).
(ii) Intracellular expression of Foxp3 transcription factor. Foxp3 expression was detected using a FITC-conjugated anti-human Foxp3 staining set (eBioscience) according to the manufacturer's instructions. An isotype-matched antibody was used as a control (eBioscience).
(iii) CD107 surface expression. To evaluate the frequency of CD4 and CD8 T cells undergoing recent degranulation, PBMC (2 ϫ 10 6 cells/ml, in complete medium) were cultured for 5 days, with or without M. tuberculosis (2:1 ratio of M. tuberculosis to PBMC). FITC-labeled anti-CD107 MAb (BD Pharmingen) was then added directly to tubes, and cells were incubated for a further 4 h at 37°C in a 5% CO 2 incubator. After that, cells were washed and stained for CD4 and CD8 expression.
(iv) Intracellular cytokine expression. Intracellular IL-10, IL-4, and IFN-␥ expression was determined in 5-day-old PBMC cultures. Briefly, brefeldin A (5 g/ml; Sigma Chemical Co., St. Louis, MO) was added for the last 4 h of culture to block cytokine secretion, and cells were surface stained with anti-CD4 and anti-CD8. They then were fixed with 0.5% paraformaldehyde and permeabilized with fluorescence-activated cell sorter permeabilizing solution 2 (BD Bioscience) before FITC-or PE-conjugated anti-IL-10, anti-IL-4 (both from BD Bioscience), or anti-IFN-␥ (Caltag, Burlingame, CA) was added. Statistical analysis. Data were expressed as medians and 25th to 75th percentiles. The analysis was performed using the nonparametric Kruskal-Wallis test to compare responses of MDR-TB and S-TB patients and healthy individuals, followed by the Mann-Whitney U test to compare two groups. The Friedman test was performed to compare responses to different treatments within each group, followed by the Wilcoxon test. Correlations between CD107 and cytokine expression were analyzed by the nonparametric Spearman's rank test. All statistical analyses were two sided, and the significance level adopted was for P values of Ͻ0.05. The analysis was performed using the statistical software SPSS 15.0 for Windows (SPSS Inc., IL) and Graphpad Prism 4.0 (Graphpad Software Inc., CA).
RESULTS

Strains M and Ra induce differential IL-10, IL-4, and IFN-␥ expression in CD4
؉ and CD8 ؉ T cells. To assess the immune profiles induced by M. tuberculosis, intracellular expression of IL-10, IL-4, and IFN-␥ was determined in PBMC from MDR-TB and S-TB patients and healthy controls (group N) after stimulation with or without strain H37Rv, M, or Ra for 5 days. As shown in Fig. 2 . Conversely, no differences were observed between both groups of MDR-TB patients for H37Rv-or Ra-induced IL-4 ϩ cells. Thus, the ability to induce high IL-4 levels in TB patients seems to be an intrinsic characteristic of strain M. CD4 ϩ and CD8 ϩ cells expressing IFN-␥ were increased above basal levels upon PBMC stimulation with H37Rv, M, and Ra in S-TB patients and group N controls, whereas in MDR-TB patients, CD8
ϩ IFN-␥ ϩ cell enhancement was achieved only by H37Rv and M stimulation (Fig. 4) . Moreover, a reduction in the number of M. tuberculosis-induced IFN-␥ ϩ cells was observed in TB patients compared to that in PPD ϩ healthy controls. Furthermore, strain H37Rv was the best IFN-␥ inducer in CD4 ϩ cells from healthy PPD ϩ controls, whereas the strain made no difference in the induction of CD8 ϩ IFN-␥ ϩ cells.
Strain M induces low CD107 expression in CD8
؉ T cells. CD107a expression on the cell surface has been described as a marker of cytotoxic CD8 ϩ T-cell degranulation/activation (2). CD107a and -b are intracellular proteins normally found in lysosomes that are transiently expressed on CTL surfaces upon exocytosis of cytotoxic granules (60) . Considering that in our system CD8 ϩ T cells are in close contact with antigen-presenting cells, we evaluated the presence of CD8 ϩ T cells having undergone recent granule exocytosis in 5-day-old PBMC cultures by employing a CD107 mobilization assay. As shown in Fig. 5A , the proportion of CD107 ϩ cells in CD8 ϩ T cells increased in TB patients and group N controls upon H37Rv, M, and Ra stimulation. However, TB patients showed fewer CD107 ϩ cells than did group N controls. Moreover, strain M induced the lowest CD107 expression not only in TB patients but also in group N controls, suggesting that this strain has an impaired ability to evoke a CTL response. These results were confirmed in group N controls by employing a standard 51 Cr release cytotoxicity assay (Fig. 5B) .
Considering that CD107 upregulation has been demonstrated to be in concordance with perforin loss and enhanced IFN-␥ production (2), we compared the proportions of IFN-␥ and CD107 on antigen-stimulated CD8 ϩ T cells from MDR-TB and S-TB patients and group N controls. A significant correlation between both markers was observed, with that for strains H37Rv and M being weaker. This suggests that impaired CD107 expression could be related to diminished IFN-␥ expression in CD8 ϩ T cells from TB patients (Fig. 5C ). In contrast, an inverse correlation between the proportions of CD107 ϩ and IL-4 ϩ or IL-10 ϩ cells in the CD8 ϩ cell subset was found.
Having observed that strain M induced weak IFN-␥ expression in group N controls, low CTL activity in group N controls and TB patients, and strong IL-4 expression in TB patients, we wondered whether these characteristic patterns were strain specific or, in contrast, were shared with other related MDR strains of the Haarlem family. For this purpose, we evaluated the same effector functions, but using strain 410, a Haarlem strain that is highly related to strain M but has rarely caused disease since the latter started clonal expansion. ϩ T-cell population from TB patients compared to that from group N controls. In contrast, the proportions of CD25 ϩ cells within CD8 ϩ T cells were similar among TB patients and group N controls ( Table 1) .
The proportions of conventional activated CD4 ϩ T cells and natural Treg cells were analyzed by discriminating low or high CD25 expression on the basis of CD25 mean fluorescence intensity within the CD4 ϩ cell population. As shown in Table  1 (Table 1) ; however, Foxp3 mean fluorescence intensities were similar for all groups (data not shown). Furthermore, the proportion of ex vivo Treg cells strongly correlated with antigen load in S-TB patients (Spearman test; r ϭ 8,198; P ϭ 0.0119), while no correlation was observed for MDR-TB patients. This difference may be ascribed to the fact that MDR-TB patients constituted a much more heterogeneous population in terms of previous duration of disease and anti-TB treatment. Recently, CD8 ϩ Treg cells that are able to inhibit T-cell proliferation and cytokine production have also been described, and human CD8 ϩ CD25 ϩ Foxp3 ϩ cells have been observed in adult PBMC and in neonatal thymus (8, 52) . In line with this, we detected an increased percentage of CD8 ϩ CD25 ϩ Foxp3 ϩ cells only in MDR-TB patients (Table 1) . Altogether, our results indicate that CD4 ϩ and CD8
ϩ Treg cells are expanded in vivo in MDR-TB patients and confirm previous reports that detected CD4 ϩ Treg cell expansion in S-TB patients (6, 18, 19, 46) .
High levels of CD4 ؉ CD25 ؉ Foxp3 ؉ Treg cells are induced by M. tuberculosis strains in MDR-TB patients. We next wanted to determine whether local MDR strains were able to induce an in vitro expansion of CD4 ϩ Treg cells. To do this, PBMC from MDR-TB and S-TB patients and group N controls were stimulated for 5 days with strain H37Rv, M, or Ra, and the proportion of CD25 high Foxp3 ϩ cells in the CD4 ϩ T-cell population was evaluated. As shown in Fig. 6 , H37Rv, M, and Ra enhanced CD4 ϩ CD25 high Foxp3 ϩ cells in TB patients and group N controls; however, MDR-TB patients showed higher percentages of H37Rv-and M-induced Treg cells than did group N controls. Thus, outbreak MDR strains M and Ra induce Treg cells, like H37Rv does, with the highest Treg cell expansion observed in MDR-TB patients.
Treg cells suppress effector functions of PBMC from TB patients. Finally, we evaluated whether circulating Treg cells suppressed M. tuberculosis-induced responses, such as cytokine production and CD107a degranulation, in TB patients. Depletion of CD25 ϩ cells enhanced the percentages of H37Rv-, M-, or Ra-induced CD4 ϩ IFN-␥ ϩ and CD8 ϩ IFN-␥ ϩ cells (Fig. 7 ) and decreased the proportions of CD4 ϩ IL-10 ϩ and CD8 ϩ IL-10 ϩ cells (Fig. 8) in TB patients, whereas CD25 depletion did not modify the level of IL-4 ϩ cells (data not shown). In addition, CD25 depletion also increased M. tuberculosis-induced CD8 ϩ CD107 ϩ T cells in TB patients (Fig. 9) , suggesting that CD25
ϩ Treg cells are functionally active in TB, upregulating IL-10 and inhibiting IFN-␥ expression and CTL degranulation. In spite of CD25 depletion, degranulation induced by the M and Ra strains was still lower in MDR-TB patients than in S-TB patients and group N controls. Moreover, strain M induced lower CD107 expression than did H37Rv in MDR-TB patients (P Ͻ 0.05) and group N controls (P Ͻ 0.05), and Ra also induced less degranulation than did H37Rv in MDR-TB patients (P Ͻ 0.05), even in the absence of Treg cells.
DISCUSSION
The development of TB disease depends on a subtle balance between host genetic factors involved in susceptibility and re- (4, 16, 25, 26, 33) and increased IL-4 production by CD4 ϩ T cells stimulated by a lipid extract of H37Rv (50) . Likewise, in our study, both MDR-TB and S-TB patients showed an impaired expression of IFN-␥ in CD4 ϩ and CD8 ϩ T cells, irrespective of the tested strain; therefore, this might be ascribed to the altered Th1/Th2 profile characteristic of advanced disease (13) . In contrast to the work of McDyer et al. (33), we found diminished IFN-␥ expression in MDR-TB patients, in spite of their normal CD4 ϩ counts of Ͼ500/l. Moreover, high IL-4 levels were observed in CD4 ϩ and CD8
ϩ cells from MDR-and S-TB patients, with M being the best inducer, suggesting that this strain exploits and enhances the preexisting tendency of TB patients to mount a Th2 response. Moreover, the fact that patients infected with strain M showed more CD4 ϩ and CD8 ϩ IL-4 ϩ cells highlights the peculiar ability of this strain to bias the Th1 response through IL-4 induction. High IL-4 levels have been associated with progression from latent infection to active disease (35, 54) , advanced radiological disease, and cavitary TB (49, 57) . In this context, IFN-␥ deficiency in TB patients could be due to a shift to a Th2 cytokine profile, undermining the efficacy of Th1-mediated immunity and causing immunopathology (47) . Similarly, IL-4 and IL-13 were found to be induced in human monocytes by virulent Beijing strains (30) , and differences in Th1/Th2 profile have been observed in healthy individuals with single-copy IS6110-carrying strains from South India (41, 42) and in TB patients infected with non-Beijing or Beijing strains (56) . Hence, the overall T-cell response to M. tuberculosis strains seems to be dependent on the host ability to mount Th1/Th2 responses and the potential of each strain to increase the Th2 cytokine profile in susceptible individuals. CTL activity has been associated with lysis of M. tuberculosisinfected macrophages and direct killing of mycobacteria (12, 55) . Here we observed that MDR-and S-TB patients failed to induce degranulation of CD8 ϩ cells and to evoke a CTL response, likely due to the high Th2 profile induced in CD4 ϩ and CD8 ϩ cells from these patients. In line with this, a gradual loss of CD8-mediated CTL activity against autologous H37Rv-pulsed macrophages dependent on IL-10 production has been observed in patients with active S-TB (10-12), and modulation of Mycobacterium leprae Hsp65-induced CTL activity by IL-10 and IL-4 has also been observed in leprosy patients (11) . In addition, IL-4 leads to development of a CD8 ϩ T-cell subset that fails to upregulate granzyme B, a potent apoptosis-inducing protease of CTLs (44) . A Th2 cytokine profile is a suitable explanation for the weak cytotoxic activity detected in MDRand S-TB patients but does not account for the inability of strain M to induce cytotoxicity in healthy controls. To shed further light on this finding, we examined another MDR-TB strain with a close genetic link with M, but which is epidemiologically incompetent, namely, strain 410. In healthy controls, these two highly related Haarlem strains showed similar IL-10, IL-4, and IFN-␥ expression patterns; however, they differed in cytotoxic activity. Thus, CTL impairment is a hallmark of strain M, and deficient lysis of infected macrophages could be one of multiple factors involved in strain M fitness. Current studies are being performed to evaluate the mechanisms employed by strain M to hamper the CTL response.
It has been speculated that Treg cells might play important regulatory functions in the immune response (48) . Herein, we observed an increase in circulating CD4 ϩ CD25 high Foxp3 ϩ cells in MDR-TB and S-TB patients, as previously demonstrated (6, 18, 19, 46) . In addition, we also showed an increase in CD8 ϩ CD25 ϩ Foxp3 ϩ cells in MDR-TB patients, although their levels were threefold lower than those of CD4 ϩ Treg cells. Accordingly, a CD8 ϩ regulatory T-cell subset was recently described as capable of mediating suppression of Mycobacterium bovis BCG-induced PBMC proliferation in PPD ϩ healthy individuals and in M. tuberculosis-infected lymph nodes and tonsils (22) . Furthermore, as demonstrated with heatkilled strain Erdman and BCG (17, 20) , strains M and Ra expanded Treg cells in PBMC from MDR-TB and S-TB patients and healthy tuberculin reactors, like H37Rv did, showing that this expansion is not M. tuberculosis genotype dependent. The marked Treg cell expansion observed in MDR-and S-TB patients could be related to the high IL-4 levels induced by M. tuberculosis, which is in accordance with CD4 ϩ CD25 ϩ Treg cell induction from CD25
Ϫ peripheral blood T cells by IL-4 (53). Treg cell depletion decreased IL-10 and enhanced IFN-␥ levels in CD4 ϩ and CD8 ϩ T cells from TB patients, suggesting that Treg cells may suppress effector functions. Indeed, Treg cell depletion also enhanced CD107 ϩ CD8 ϩ cells in MDRand S-TB patients, as also observed in mice (34) . Furthermore, low M-and Ra-induced CD107 expression and IFN-␥ upregulation were still observed in MDR-TB patients in the absence of Treg cells, suggesting that additional factors could inhibit the Th1 response. Despite the presence of Treg cells, high proportions of CD4 ϩ and CD8 ϩ IL-4 ϩ cells were induced by M. tuberculosis strains in MDR-TB patients; therefore, it is likely that this cytokine could interfere with CTL differentiation or functionality. In line with this, Th2 T-cell clones have been shown to be less susceptible to the suppressive activity of CD25 ϩ regulatory thymocytes (7) . The fact that Treg cell depletion did not restore either Ra-or M-induced CD107 to group N levels in MDR-TB patients suggests that the impairment of CTL activity and cytokine production could not be ascribed exclusively to Treg cell suppression.
In summary, we have demonstrated an increased frequency of circulating Treg cells in MDR-TB patients that are expanded in vitro by M. tuberculosis stimulation independent of the strain and that suppress antigen-induced IFN-␥ and CTL responses. Outbreak MDR strain M is a weak IFN-␥ inducer. Remarkably, the inability to develop CTL activity is a hallmark of strain M, regardless of its ability to induce IFN-␥ in CD8 ϩ cells in healthy PPD ϩ controls. Hence, impairment of CTL activity may be an evasion mechanism employed by strain M to avoid macrophage lysis by antigen-specific CTLs. Altogether, these results suggest that immune responses to M and Ra outbreak strains are the result of the host's ability to mount an FIG. 9 . CD25 depletion enhances CD107 expression on antigen-stimulated CD4 ϩ and CD8 ϩ T cells. PBMC from 10 MDR-TB and 8 S-TB patients and 6 group N controls were depleted of CD25 ϩ cells by magnetic methods. PBMC (white bars) and CD25-depleted cells (gray bars) were cultured for 5 days with H37Rv, M, or Ra and tested for CD107 expression. Results are expressed as % CD107
ϩ cells in CD8 ϩ T cells (medians and 25th to 75th percentiles). †, P Ͻ 0.05 for PBMC versus CD25-depleted PBMC; a, P Ͻ 0.05 for MDR-TB patients versus group N controls; #, P Ͻ 0.05 for MDR-TB versus S-TB patients.
efficient immune response and the potential of different M. tuberculosis genotypes to drive Th1 or Th2 profiles.
